254 related articles for article (PubMed ID: 29974956)
1. Infectious and immunological sequelae of daratumumab in multiple myeloma.
Johnsrud AJ; Johnsrud JJ; Susanibar SA; Kamimoto JJ; Kothari A; Burgess M; Van Rhee F; Rico JC
Br J Haematol; 2019 Apr; 185(1):187-189. PubMed ID: 29974956
[No Abstract] [Full Text] [Related]
2. Daratumumab combination prolongs myeloma survival.
Das M
Lancet Oncol; 2016 Oct; 17(10):e422. PubMed ID: 27601427
[No Abstract] [Full Text] [Related]
3. Daratumumab in multiple myeloma.
Nooka AK; Kaufman JL; Hofmeister CC; Joseph NS; Heffner TL; Gupta VA; Sullivan HC; Neish AS; Dhodapkar MV; Lonial S
Cancer; 2019 Jul; 125(14):2364-2382. PubMed ID: 30951198
[TBL] [Abstract][Full Text] [Related]
4. Monoclonal Antibodies in Multiple Myeloma: A New Wave of the Future.
Sherbenou DW; Mark TM; Forsberg P
Clin Lymphoma Myeloma Leuk; 2017 Sep; 17(9):545-554. PubMed ID: 28734795
[TBL] [Abstract][Full Text] [Related]
5. Aseptic Meningitis as a Complication of Daratumumab Therapy.
Reddy K; Htut M; Krishnan A; Dadwal SS
Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):e333-e335. PubMed ID: 29903471
[No Abstract] [Full Text] [Related]
6. Daratumumab improves survival in multiple myeloma.
Baker H
Lancet Oncol; 2016 Nov; 17(11):e480. PubMed ID: 27746105
[No Abstract] [Full Text] [Related]
7. A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab.
Mikhael J; Belhadj-Merzoug K; Hulin C; Vincent L; Moreau P; Gasparetto C; Pour L; Spicka I; Vij R; Zonder J; Atanackovic D; Gabrail N; Martin TG; Perrot A; Bensfia S; Weng Q; Brillac C; Semiond D; Macé S; Corzo KP; Leleu X
Blood Cancer J; 2021 May; 11(5):89. PubMed ID: 33980831
[No Abstract] [Full Text] [Related]
8. Systematic review and meta-analysis of the efficacy and safety of novel monoclonal antibodies for treatment of relapsed/refractory multiple myeloma.
Zhang T; Wang S; Lin T; Xie J; Zhao L; Liang Z; Li Y; Jiang J
Oncotarget; 2017 May; 8(20):34001-34017. PubMed ID: 28454113
[TBL] [Abstract][Full Text] [Related]
9. A multicenter review of infusion-related reactions to daratumumab for relapsed multiple myeloma in the real world setting.
Geirnaert M; Howarth J; Martin K; Ricard C; Streilein S; Wasney D; Dao V; Kotb R; Rimmer E; Minuk L
J Oncol Pharm Pract; 2021 Jun; 27(4):907-910. PubMed ID: 33108988
[TBL] [Abstract][Full Text] [Related]
10. Advancement in monoclonal antibody therapy for multiple myeloma.
Shigle TL; Bashir Q
Lancet Haematol; 2020 May; 7(5):e354-e355. PubMed ID: 32213343
[No Abstract] [Full Text] [Related]
11. Preemptive therapy for cytomegalovirus reactivation after daratumumab-containing treatment in patients with relapsed and refractory multiple myeloma.
Nakagawa R; Onishi Y; Kawajiri A; Onodera K; Furukawa E; Sano S; Saito K; Ichikawa S; Fujiwara T; Fukuhara N; Harigae H
Ann Hematol; 2019 Aug; 98(8):1999-2001. PubMed ID: 30824957
[No Abstract] [Full Text] [Related]
12. Daratumumab for the Treatment of Multiple Myeloma.
Plesner T; Krejcik J
Front Immunol; 2018; 9():1228. PubMed ID: 29915586
[TBL] [Abstract][Full Text] [Related]
13. Current use of monoclonal antibodies in the treatment of multiple myeloma.
Varga C; Maglio M; Ghobrial IM; Richardson PG
Br J Haematol; 2018 May; 181(4):447-459. PubMed ID: 29696629
[TBL] [Abstract][Full Text] [Related]
14. Adaptive Natural Killer Cells Facilitate Effector Functions of Daratumumab in Multiple Myeloma.
Cho H; Kim KH; Lee H; Kim CG; Chung H; Choi YS; Park SH; Cheong JW; Min YH; Shin EC; Kim JS
Clin Cancer Res; 2021 May; 27(10):2947-2958. PubMed ID: 33602683
[TBL] [Abstract][Full Text] [Related]
15. Clinical and Pharmacologic Features of Monoclonal Antibodies and Checkpoint Blockade Therapy in Multiple Myeloma.
D'Agostino M; Gazzera G; Cetani G; Bringhen S; Boccadoro M; Gay F
Curr Med Chem; 2019; 26(32):5968-5981. PubMed ID: 29756564
[TBL] [Abstract][Full Text] [Related]
16. Magic year for multiple myeloma therapeutics: Key takeaways from the ASH 2015 annual meeting.
Zhang K; Desai A; Zeng D; Gong T; Lu P; Wang M
Oncotarget; 2017 Feb; 8(6):10748-10759. PubMed ID: 27863374
[TBL] [Abstract][Full Text] [Related]
17. In vivo vaccination effect in multiple myeloma patients treated with the monoclonal antibody isatuximab.
Atanackovic D; Yousef S; Shorter C; Tantravahi SK; Steinbach M; Iglesias F; Sborov D; Radhakrishnan SV; Chiron M; Miles R; Salama M; Kröger N; Luetkens T
Leukemia; 2020 Jan; 34(1):317-321. PubMed ID: 31409922
[No Abstract] [Full Text] [Related]
18. Immunotherapy: A New Approach to Treating Multiple Myeloma with Daratumumab and Elotuzumab.
Afifi S; Michael A; Lesokhin A
Ann Pharmacother; 2016 Jul; 50(7):555-68. PubMed ID: 27083916
[TBL] [Abstract][Full Text] [Related]
19. A preliminary study of the anti-κ myeloma antigen monoclonal antibody KappaMab (MDX-1097) in pretreated patients with κ-restricted multiple myeloma.
Spencer A; Walker P; Asvadi P; Campbell DH; Reed K; Herbert BR; Breen EJ; Copeman MC; Dunn RD
Blood Cancer J; 2019 Jul; 9(8):58. PubMed ID: 31366914
[No Abstract] [Full Text] [Related]
20. Cytomegalovirus reactivation in patients with multiple myeloma administered daratumumab-combination regimens.
Tabata R; Sato N; Yamauchi N; Guo YM; Nakamura H; Nagata A; Song-Gi C; Minami Y; Yuda J
Ann Hematol; 2022 Feb; 101(2):465-467. PubMed ID: 33864134
[No Abstract] [Full Text] [Related]
[Next] [New Search]
